Kurt A. Jaeckle

19.5k total citations · 5 hit papers
160 papers, 11.4k citations indexed

About

Kurt A. Jaeckle is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Kurt A. Jaeckle has authored 160 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Genetics, 69 papers in Pulmonary and Respiratory Medicine and 43 papers in Oncology. Recurrent topics in Kurt A. Jaeckle's work include Glioma Diagnosis and Treatment (104 papers), Brain Metastases and Treatment (57 papers) and Cancer Treatment and Pharmacology (17 papers). Kurt A. Jaeckle is often cited by papers focused on Glioma Diagnosis and Treatment (104 papers), Brain Metastases and Treatment (57 papers) and Cancer Treatment and Pharmacology (17 papers). Kurt A. Jaeckle collaborates with scholars based in United States, Netherlands and Canada. Kurt A. Jaeckle's co-authors include Jan C. Buckner, Paul D. Brown, Karla V. Ballman, Victor A. Levin, Evanthia Galanis, Athanassios P. Kyritsis, Michael D. Prados, Kenneth R. Hess, Caterina Giannini and W.K. Alfred Yung and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Kurt A. Jaeckle

157 papers receiving 11.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases

2016 1.1k citations Paul D. Brown, Kurt A. Jaeckle et al. profile →
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

2013 742 citations Mark R. Gilbert, Meihua Wang et al. Journal of Clinical Oncology profile →
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

1999 722 citations Kurt A. Jaeckle, Michael D. Prados et al. Journal of Clinical Oncology profile →
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

2005 550 citations Evanthia Galanis, Jan C. Buckner et al. Journal of Clinical Oncology profile →
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

2011 401 citations Martin J. van den Bent, David Schiff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kurt A. Jaeckle United States	54	6.6k	4.3k	3.3k	2.7k	2.3k	160	11.4k
Karima Mokhtari France	57	7.2k 1.1×	2.6k 0.6×	3.3k 1.0×	1.6k 0.6×	2.4k 1.0×	234	10.7k
David Capper Germany	58	7.8k 1.2×	2.5k 0.6×	5.2k 1.6×	2.6k 1.0×	2.1k 0.9×	230	13.4k
Marc Sanson France	61	8.6k 1.3×	3.1k 0.7×	5.2k 1.6×	1.8k 0.7×	2.5k 1.1×	319	14.1k
S. Clifford Schold United States	49	6.0k 0.9×	2.5k 0.6×	2.5k 0.8×	1.8k 0.6×	2.3k 1.0×	112	9.8k
P Farah Lebanon	5	5.8k 0.9×	2.0k 0.5×	3.1k 1.0×	1.2k 0.5×	1.8k 0.8×	8	10.2k
Annick Desjardins United States	51	6.3k 1.0×	2.2k 0.5×	3.2k 1.0×	2.6k 1.0×	1.3k 0.6×	247	10.0k
Antonio Omuro United States	46	5.9k 0.9×	2.5k 0.6×	2.1k 0.6×	2.6k 1.0×	2.7k 1.2×	187	10.2k
Didier Frappaz France	45	4.6k 0.7×	2.1k 0.5×	2.3k 0.7×	1.0k 0.4×	2.7k 1.2×	274	8.1k
Andrew B. Lassman United States	44	5.8k 0.9×	3.0k 0.7×	1.9k 0.6×	2.1k 0.8×	1.2k 0.5×	191	8.8k
V. Peter Collins Sweden	57	4.3k 0.7×	1.6k 0.4×	4.4k 1.4×	1.7k 0.6×	2.0k 0.9×	155	10.1k

Countries citing papers authored by Kurt A. Jaeckle

Since Specialization

Citations

This map shows the geographic impact of Kurt A. Jaeckle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt A. Jaeckle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt A. Jaeckle more than expected).

Fields of papers citing papers by Kurt A. Jaeckle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kurt A. Jaeckle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt A. Jaeckle. The network helps show where Kurt A. Jaeckle may publish in the future.

Co-authorship network of co-authors of Kurt A. Jaeckle

This figure shows the co-authorship network connecting the top 25 collaborators of Kurt A. Jaeckle. A scholar is included among the top collaborators of Kurt A. Jaeckle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kurt A. Jaeckle. Kurt A. Jaeckle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kern, Steven E., Timothy F. Burns, Kurt A. Jaeckle, et al.. (2024). Tumor Treating Fields Utilization for Glioblastoma at a Large Multicenter Academic Practice. International Journal of Radiation Oncology*Biology*Physics. 120(2). e224–e225. 1 indexed citations

Galanis, Evanthia, S. Keith Anderson, Erin Twohy, et al.. (2022). Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances. 4(1). vdac041–vdac041. 6 indexed citations

Soffietti, Riccardo, Chetan Bettegowda, Ingo K. Mellinghoff, et al.. (2022). Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology. 24(6). 855–871. 63 indexed citations

Jaeckle, Kurt A., Jesse G. Dixon, Alvaro Moreno‐Aspitia, et al.. (2020). Intra‐CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Medicine. 9(21). 7935–7942. 21 indexed citations

Jaeckle, Kurt A., Erin Twohy, Jesse G. Dixon, et al.. (2019). Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of Neuro-Oncology. 143(3). 573–581. 8 indexed citations

Brown, Paul E., Anthony L. Asher, Karla V. Ballman, et al.. (2015). BMET-05NCCTG N0574 (ALLIANCE): A PHASE III RANDOMIZED TRIAL OF WHOLE BRAIN RADIATION THERAPY (WBRT) IN ADDITION TO RADIOSURGERY (SRS) IN PATIENTS WITH 1 TO 3 BRAIN METASTASES. Neuro-Oncology. 17(suppl 5). v45.5–v46. 18 indexed citations

Daniel, J., Evanthia Galanis, S. Keith Anderson, et al.. (2014). A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology. 17(9). 1261–1269. 122 indexed citations

Gilbert, Mark R., Meihua Wang, Kenneth Aldape, et al.. (2013). Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology. 31(32). 4085–4091. 742 indexed citations breakdown →

Galanis, Evanthia, S. Keith Anderson, Joon H. Uhm, et al.. (2013). Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial. Clinical Cancer Research. 19(17). 4816–4823. 127 indexed citations

10.

Massett, Holly A., et al.. (2013). Rapid online feedback to improve clinical trial accrual: CODEL anaplastic glioma (AG) (NCCTG/Alliance N0577) as a model.. Journal of Clinical Oncology. 31(15_suppl). 1596–1596. 2 indexed citations

11.

Sarkaria, Jann N., Evanthia Galanis, Wenting Wu, et al.. (2010). North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology*Biology*Physics. 81(2). 468–475. 67 indexed citations

12.

Galanis, Evanthia, Kurt A. Jaeckle, Matthew J. Maurer, et al.. (2009). Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology. 27(12). 2052–2058. 283 indexed citations

13.

Deen, H. Gordon, et al.. (2006). Removal of An Orbital Metallic Foreign Body to Facilitate Magnetic Resonance Imaging: Technical Case Report. Neurosurgery. 58(5). E999–E999. 3 indexed citations

14.

Brown, Paul D., Ashley W. Jensen, Sara J. Felten, et al.. (2006). Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade Glioma. Journal of Clinical Oncology. 24(34). 5427–5433. 69 indexed citations

15.

Prados, Michael D., Kathleen R. Lamborn, W. K. Alfred Yung, et al.. (2006). A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1. Neuro-Oncology. 8(2). 189–193. 187 indexed citations

16.

Jaeckle, Kurt A.. (2005). Improving the Outcome of Patients with Leptomeningeal Cancer: New Clinical Trials and Experimental Therapies. Cancer treatment and research. 125. 181–193. 3 indexed citations

17.

Jaeckle, Kurt A., Karla V. Ballman, Joon H. Uhm, et al.. (2004). Comparison of survival endpoints in glioblastoma patients receiving or not receiving enzyme-inducing anticonvulsants in NCCTG Trials. Journal of Clinical Oncology. 22(14_suppl). 1525–1525. 1 indexed citations

18.

Greenlee, John, et al.. (1992). Pursuing an occult carcinoma in a patient with subacute cerebellar degeneration and anticerebellar antibodies. Need for vigorous follow-up.. PubMed Central. 156(2). 199–202. 4 indexed citations

19.

Furneaux, Henry, Marc K. Rosenblum, Shirley H. Wray, et al.. (1991). Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer. Annals of Neurology. 29(3). 241–251. 279 indexed citations

20.

Jaeckle, Kurt A., et al.. (1983). Phase I study of intraventricularly administered human α interferon in patients with leptomeningeal tumor. Annals of Neurology. 14(1). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact